ArticleJournal of neuro-oncology2012
Clinical characteristics of meningiomas assessed by ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron-emission tomography.
Article in Journal of neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Prediction of Meningioma WHO Grade Using PET Findings: A Systematic Review and Meta-Analysis.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2021Pooled it
- Radioligand therapies in meningioma: Evidence and future directions.Neuro-oncology · 2024Review
- Revealing subependymal giant cell astrocytoma with multimodal positron emission tomography: illustrative cases.Journal of neurosurgery. Case lessons · 2024Article
- Advances in PET imaging for meningioma patients.Neuro-oncology advances · 2023Article
- Imaging Characteristics of Meningiomas.Advances in experimental medicine and biology · 2023Article
- Use of advanced neuroimaging and artificial intelligence in meningiomas.Brain pathology (Zurich, Switzerland) · 2022Review
- Study on intracranial meningioma using PET ligand investigation during follow-up over years (SIMPLIFY).Neuroradiology · 2021Article
- In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[European journal of nuclear medicine and molecular imaging · 2020Article
- The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.International journal of molecular sciences · 2020Review
- Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.Cancers · 2019Review
- Imaging and diagnostic advances for intracranial meningiomas.Neuro-oncology · 2019Review
- The Diagnostic Value Of UsingCancer management and research · 2019Article
- PET imaging in patients with meningioma-report of the RANO/PET Group.Neuro-oncology · 2017Review
- Diagnostic challenges in meningioma.Neuro-oncology · 2017Review
- Review
- 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?Neuro-oncology · 2016Article
- Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of (11)C-L-methionine positron emission tomography.European journal of nuclear medicine and molecular imaging · 2016Article
- Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas.Neuro-oncology · 2015Article
- Article
- Pseudo-continuous arterial spin labeling reflects vascular density and differentiates angiomatous meningiomas from non-angiomatous meningiomas.Journal of neuro-oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical course of meningioma varies from case to case, despite similar characteristics on magnetic resonance (MR) imaging. Functional imaging including (11)C-methionine and (18)F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) has been widely studied for noninvasive preoperative evaluation of brain tumors. However, few reports have examined correlations between meningiomas and findings on (11)C-methionine and FDG PET. The objective of this study was to clarify the relationship between tumor characteristics and (11)C-methionine and FDG uptake in meningiomas. For 68 meningiomas in 51 cases, (11)C-methionine uptake was evaluated by measuring both mean and maximum tumor/normal (T/N) ratio for the whole area of the tumors. FDG uptake in 44 of those meningiomas was also analyzed. Tumor size was measured volumetrically, and tumor-doubling time was estimated. Histopathological evaluation was performed in 19 surgical cases. Mean and maximum T/N ratios of (11)C-methionine PET were significantly higher in skull-base lesions than in non-skull-base lesions. Correlations of mean and maximum T/N ratio of (11)C-methionine PET with tumor-doubling time, MIB-1 labeling index, microvessel density and World Health Organization grading were not significant. Mean T/N ratio of (11)C-methionine PET correlated significantly with tumor volume according to logarithm regression modeling (P < 0.0001, R = 0.544). However, mean and maximum T/N ratio of FDG-PET correlated with none of the tumor characteristics described above. These results suggest that (11)C-methionine uptake correlates with tumor volume, but not with tumor aggressiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.